
Regional Office Manager Vaco LLC
- $125,000–$150,000 Per Year
| Location | Burlington, MA |
Position Summary
The Office Manager is fully responsible for the day‑to‑day operations, efficiency, and overall workplace experience across all MBX office locations, including lab-related partnerships and needs. This role ensures a well‑functioning, organized, and engaging environment by proactively managing office functions, vendor relationships, space utilization, and onsite logistics. In addition to overseeing multi‑site operations, the Office Manager plays a key role in coordinating Together Weeks and other company‑wide initiatives that strengthen the employee experience and foster a connected MBX community. They also support the planning and execution of large meetings and events, enabling seamless collaboration.
The Office Manager owns all aspects of office operations and outcomes, acting as a strategic partner in shaping the workplace to support productivity, connection, and company culture. They are expected to anticipate needs, solve problems proactively, and continuously improve the workplace experience to meet evolving business and employee demands.
Key Responsibilities
Education & Qualifications
Travel:
This position requires on-site work an average of four days a week. You will be expected to travel periodically based on the needs of the business to the extent requested by the Company, including attendance at Together Weeks, Together Days, and functional meetings as requested by the Company.
Company Overview:
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
EEO Statement:
MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.


